Clinical Trial Update: A Phase II Study of AT7519M, a CDK Inhibitor, in Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia [Phase 2]

View source ↗

Summary

Phase II study evaluating AT7519M, a CDK inhibitor, in relapsed/refractory Chronic Lymphocytic Leukemia has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia

Drugs mentioned

• AT7519M

Snippet

Sponsor: NCIC Clinical Trials Group | Conditions: Chronic Lymphocytic Leukemia | Phase 2 | Status: COMPLETED